NV-ENCONNEX
21.11.2019 17:02:07 CET | Business Wire | Press release
Enconnex announced today that it has acquired assets of Active Energy Solutions (AES), a division of Methode Electronics, Inc., solidifying the long-term relationship between the two firms. Under an exclusive distribution agreement with AES, Enconnex has been offering the AC6000 uninterruptible power supply (UPS) to its customers. Enconnex has established a new manufacturing facility in its Reno, Nev., headquarters and incorporated the product into its integrated data center solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191121005220/en/
“This acquisition is the logical extension of our strategic partnership with AES,” said Thane Moore, Director of Product Line Management, Enconnex. “The AC6000 is a robust yet eco-friendly UPS that offers the advanced features needed to support today’s IT and Data Center demands. We are also providing a firmware upgrade release to all existing customers of the AC6000 allowing them to benefit with the latest advancements.”
The AC6000 is the first line-interactive UPS that both protects IT equipment from power outages and supplements the electrical grid during periods of peak energy consumption with its peak shave technology. Its industrial-grade lithium-ion battery pack supplies up to 6kW of power for six full minutes — 330 percent longer than legacy lead-acid batteries. It offers fast recharge to 90 percent in less than one hour, and delivers up to seven years of maintenance-free battery life. It’s up to 75 percent lighter than UPSs that use lead-acid batteries, and has a compact design that takes up just 2U of rack space in the data center.
The patent-pending peak shave technology in the AC6000 uses advanced energy management techniques to transfer to battery power during peak loads, thus reducing overall energy costs. The AC6000 is designed to maintain battery cell power balance, and it provides integrated safety electronics and thermal management for individual cells. It features a multifunctional LCD panel that displays critical performance metrics and alerts, and it supports serial and SNMP communications for remote monitoring and management.
“With low total cost of ownership, substantial energy savings and pricing that’s competitive with lead-acid products, the AC6000 delivers ROI in as little as two years,” Moore said. “Its lithium-ion battery pack delivers greater energy efficiency and more than seven year battery life while taking up less space within the data center cabinet. We believe this is the ideal solution for both modern web-scale data centers and edge computing applications where space is at a premium.”
The AC6000 is CE and UL listed and is available for purchase across the globe. To learn more about the AC6000 and purchase today, visit Enconnex AC6000 UPS .
About Enconnex
Enconnex designs and manufactures high-quality, cost-efficient solutions for data center infrastructure, including racks, cabinets and accessories, and connectivity, power, cooling and containment products. Enconnex also integrates cutting-edge solutions from a short list of technology partners who are recognized as industry leaders. Headquartered in Reno, Nev., Enconnex has offices and distribution facilities strategically located worldwide to serve the needs of its global customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005220/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom